
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations

